SCHEMBL5560756

SCHEMBL5560756

Cc1c([C@@H](C)C(=O)NC(C)(C)C(=O)O)c2c(F)c(O)ccc2n1C(=O)c1cccc(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.37
AKR1C2 P52895 2/20 0.37
HTT P42858 3/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPT P10636 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
HPGD P15428 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
TSHR P16473 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP3A4 P08684 2/20 0.32
PIK3CD O00329 1/20 0.32
LMNA P02545 2/20 0.31
KCNH2 Q12809 1/20 0.31
PLA2G7 Q13093 1/20 0.31
SLC22A12 Q96S37 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5560759 1.00 AKR1C3 (0.37) AKR1C3AKR1C2HTTNPC1RAB9A
SCHEMBL5560353 0.91 SLC6A2 (0.34) AKR1C3AKR1C2SMN1; SMN2KCNH2ALDH1A1
SCHEMBL5560356 0.91 SLC6A2 (0.34) AKR1C3AKR1C2SMN1; SMN2KCNH2ALDH1A1
SCHEMBL5554553 0.91 AKR1C3 (0.37) AKR1C3AKR1C2HTTNPC1RAB9A
SCHEMBL5561252 0.89 AKR1C3 (0.35) AKR1C3AKR1C2HTTNPC1RAB9A
SCHEMBL5561259 0.89 AKR1C3 (0.35) AKR1C3AKR1C2HTTNPC1RAB9A
SCHEMBL5554343 0.88 CHRNA1 (0.34) AKR1C3AKR1C2MEN1KMT2ASLC22A12
SCHEMBL5554341 0.88 CHRNA1 (0.34) AKR1C3AKR1C2MEN1KMT2ASLC22A12
SCHEMBL5559481 0.87 SMN1; SMN2 (0.36) AKR1C3AKR1C2HTTNPC1RAB9A
SCHEMBL5559486 0.87 SMN1; SMN2 (0.36) AKR1C3AKR1C2HTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1643961-A4 COX-2 AND FAAH INHIBITORS MICROBIA INC (US) 2007-09-12 EP disclosed
WO-2006050120-A2 SYNTHESIS OF COX-2 AND FAAH INHIBITORS MICROBIA, INC. (US) 2006-05-11 WO disclosed
EP-1643961-A2 COX-2 AND FAAH INHIBITORS Microbia, Inc. (US) 2006-04-12 EP disclosed
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed
US-20050032747-A1 COX-2 and FAAH inhibitors POLYMER CONCEPTS TECHNOLOGIES PBY, INC. 2005-02-10 US disclosed
WO-2005002525-A2 COX-2 AND FAAH INHIBITORS MICROBIA, INC. (US) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032747-A1 COX-2 and FAAH inhibitors FAAH2, FAAH, PTGS2 AKR1C3 585/4885AKR1C2 342/4885HTT 2867/4885
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 AKR1C3 577/4885AKR1C2 563/4885HTT 3263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.